等待開盤 09-24 09:30:00 美东时间
-0.260
-3.71%
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
09-23 22:23
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Init...
09-08 20:35
Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing package. Quoin Pharmaceuticals shares are climbing with conviction. What’s behind QNRX gains? Positiv...
08-28 21:40
Shares of Elastic NV (NASDAQ:ESTC) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY27 guidance. Elastic posted quarterly adjusted earnings of 70 cents per share, beating market estimates of 58 cents per share. The co...
08-28 18:31
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.61) by 18.01 percent. This is a 69.75 percent increase over losses of $(6.28) per share from the same period last year.
08-14 20:33
Vivakor, Inc.涨-9.67%;Quoin Pharmaceuticals. Ltd Sponsored ADR涨-9.29%;中驰车福涨-9.09%
06-26 08:05
Shares of Leifras Co Ltd (NASDAQ:LFS) rose sharply in pre-market trading after the company announced it will acquire SWIFT JAPAN for around JPY454.6 million. Leifras shares jumped 23.2% to $2.76 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Megan Holdings Lt...
06-24 16:44
智能充电涨-29.45%;Rubico Inc.涨-15.73%;Cerebras Systems涨-11.98%
06-24 08:05
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally approved QYLEKI™ as the proposed brand name for QRX003, ...
06-23 20:31
The IND submission is supported by clinical observations from Quoin's ongoing investigator-led pediatric PSS study. The initial subject has been treated with QRX003 for over 15 months and significant clinical
06-02 20:36